Cooperman reports 6.6% stake in DiaMedica
DiaMedica Therapeutics investor Leon G. Cooperman reports beneficial ownership of 3,450,000 voting common shares, representing 6.6% of the company’s outstanding shares based on 52,077,439 shares outstanding as of November 10, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
DiaMedica Therapeutics investor Leon G. Cooperman reports beneficial ownership of 3,450,000 voting common shares, representing 6.6% of the company’s outstanding shares based on 52,077,439 shares outstanding as of November 10, 2025. The stake consists of 2,450,000 shares held directly by Mr. Cooperman and 1,000,000 shares held by The Leon and Toby Cooperman Foundation, a charitable trust where he is a trustee. He reports sole voting and dispositive power over all 3,450,000 shares and certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of DiaMedica.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of DiaMedica Therapeutics (DMAC) does Leon Cooperman’s stake represent?
Is Leon Cooperman’s DiaMedica (DMAC) position intended to influence control of the company?
What type of SEC filing did Leon Cooperman submit for his DiaMedica (DMAC) holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.